OncoMatch

OncoMatch/Clinical Trials/NCT07761871

Exercise and Nutritional Intervention in Patients With Melanoma Receiving Immunotherapy

Is NCT07761871 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for melanoma.

NARecruitingInstitute of Oncology LjubljanaNCT07761871Data as of Sep 2026Location: Slovenia

The purpose of this randomized study is to evaluate whether a six-month program of structured resistance exercise combined with individualized nutritional support can preserve or improve skeletal muscle mass and muscle quality in adults with stage II to IV malignant melanoma who are starting treatment with immune checkpoint inhibitors. Participants will be randomly assigned either to the exercise and nutritional intervention in addition to standard oncology care or to standard oncology care alone. The study aims to obtain complete measurements from at least 40 participants. Assessments will be performed at baseline, after 3 months, and after 6 months. They will include magnetic resonance imaging of the thigh, dual-energy X-ray absorptiometry, bioelectrical impedance analysis, indirect calorimetry, clinical data, and patient-reported outcomes. The study will compare changes in skeletal muscle mass and volume, fatty infiltration of skeletal muscle, sarcopenia, body composition, resting energy expenditure, quality of life, fatigue, treatment tolerance, treatment delays, and early treatment discontinuation between the two groups. Treatment with immune checkpoint inhibitors is provided as part of routine clinical care and is not the investigational intervention.

Check if I qualify

Extracted eligibility criteria

Cancer type

Melanoma

Disease stage

Required: Stage II, III, IV

Prior therapy

Cannot have received: immune checkpoint inhibitor

Previous treatment with immune checkpoint inhibitors or disease recurrence after previous treatment with immune checkpoint inhibitors

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07761871 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior immune checkpoint inhibitor disqualifies patients from enrollment.

What disease stage is eligible?

Stage II or III or IV is required.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Related pages

Melanoma trials